The Treat-to-Target Project in Atopic Dermatitis: One Year On
DOI:
https://doi.org/10.2340/actadv.v103.5382Keywords:
atopic dermatitis, consensus, systemic treatment, treat-to-targetAbstract
Atopic dermatitis is a chronic skin condition for which a range of systemic treatments have recently been approved. A treat-to-target strategy has been developed previously alongside an algorithm to guide the management of patients with atopic dermatitis. Here, we review the strategy and algorithm in the context of the evolving therapeutic landscape, and identify areas for further refinement and development.
Downloads
References
Wollenberg A, Barbarot S, Bieber T, Christen-Zaech S, Deleuran M, Fink-Wagner A, et al. Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part I. J Eur Acad Dermatol Venereol 2018; 32: 657-682.
https://doi.org/10.1111/jdv.14891 DOI: https://doi.org/10.1111/jdv.14891
Wollenberg A, Barbarot S, Bieber T, Christen-Zaech S, Deleuran M, Fink-Wagner A, et al. Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part II. J Eur Acad Dermatol Venereol 2018; 32: 850-878.
https://doi.org/10.1111/jdv.14888 DOI: https://doi.org/10.1111/jdv.14888
De Bruin-Weller M, Biedermann T, Bissonnette R, Deleuran M, Foley P, Girolomoni G, et al. Treat-to-target in atopic dermatitis: an international consensus on a set of core decision points for systemic therapies. Acta Derm Venereol 2021; 101: adv00402.
https://doi.org/10.2340/00015555-3751 DOI: https://doi.org/10.2340/00015555-3751
Larsen HH, Vittrup I, Ruge IF, Elberling J, Skov L, Ibler K, et al. Severe and ChRonic Atopic dermatitis Treatment CoHort (SCRATCH): a Danish real-world evidence atopic dermatitis treatment registry. Acta Derm Venereol 2022; 102: adv00760.
https://doi.org/10.2340/actadv.v102.915 DOI: https://doi.org/10.2340/actadv.v102.915
Bagel J, Nguyen TQ, Lima H, Jain N, Pariser DM, Hsu S, et al. Baseline Demographics and Severity and Burden of Atopic Dermatitis in Adult Patients Initiating Dupilumab Treatment in a Real-World Registry (PROSE). Dermatol Ther (Heidelb) 2022; 12: 1417-1430.
https://doi.org/10.1007/s13555-022-00742-w DOI: https://doi.org/10.1007/s13555-022-00742-w
Siegels D, Haufe E, Heinrich L, Werfel T, Weidinger S, Schmitt J; TREATgermany Study Group. Status report on the atopic dermatitis registry TREATgermany. Allergol Select 2021; 5: 274-286.
https://doi.org/10.5414/ALX02262E DOI: https://doi.org/10.5414/ALX02262E
Ariëns LFM, van der Schaft J, Spekhorst LS, Bakker DS, Romeijn GLE, Kouwenhoven TA, et al. Dupilumab shows long-term effectiveness in a large cohort of treatment-refractory atopic dermatitis patients in daily practice: 52-week results from the Dutch BioDay registry. J Am Acad Dermatol 2021; 84: 1000-1009.
https://doi.org/10.1016/j.jaad.2020.08.127 DOI: https://doi.org/10.1016/j.jaad.2020.08.127
Abuabara K, Silverberg JI, Simpson EL, Paller AS, Eichenfield LF, Bissonnette R, et al. International observational atopic dermatitis cohort to follow natural history and treatment course: TARGET-DERM AD study design and rationale. BMJ Open 2020; 10: e039928.
https://doi.org/10.1136/bmjopen-2020-039928 DOI: https://doi.org/10.1136/bmjopen-2020-039928
Thyssen JP, Vestergaard C, Deleuran M, de Bruin-Weller MS, Bieber T, Taieb A, et al. European Task Force on Atopic Dermatitis (ETFAD): treatment targets and treatable traits in atopic dermatitis. J Eur Acad Dermatol Venereol 2020; 34: e839-e842.
https://doi.org/10.1111/jdv.16716 DOI: https://doi.org/10.1111/jdv.16716
Published
How to Cite
License
Copyright (c) 2023 Marjolein de Bruin-Weller, Mette Deleuran, Tilo Biedermann, Robert Bissonnette, Peter Foley, Giampiero Girolomoni, Jana Hercogová, Chih-Ho Hong, Norito Katoh, Andrew Pink, Marie-Aleth Richard, Stephen Shumack, Juan Francisco Silvestre, Jacob P. Thyssen, Stephan Weidinger
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All digitalized ActaDV contents is available freely online. The Society for Publication of Acta Dermato-Venereologica owns the copyright for all material published until volume 88 (2008) and as from volume 89 (2009) the journal has been published fully Open Access, meaning the authors retain copyright to their work.
Unless otherwise specified, all Open Access articles are published under CC-BY-NC licences, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material for non-commercial purposes, provided proper attribution to the original work.